Literature DB >> 19890026

T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency.

Eirik Bratland1, Beate Skinningsrud, Dag E Undlien, Edna Mozes, Eystein S Husebye.   

Abstract

CONTEXT: Autoimmune Addison's disease is thought to result from T cell mediated autoimmunity. Autoantibodies against the steroidogenic cytochrome P450 enzyme 21-hydroxylase (21OH) are found in most patients, and 21OH is therefore a likely target for antigen-specific T cells.
OBJECTIVE: The aim was to study cellular immunity to 21OH and its associations with 21OH autoantibodies and human leukocyte antigen alleles in autoimmune Addison's disease. DESIGN/PATIENTS: Peripheral blood mononuclear cells were collected from 33 patients with autoimmune Addison's disease and 21 controls. Cellular proliferation and production of cytokines in response to stimulation with 21OH or 21OH-derived peptides were tested.
RESULTS: Cellular proliferation (P = 0.0009) and secretion of interferon-gamma (P < 0.0001) in response to 21OH was significantly higher in patients compared to healthy controls and associated with the presence of 21OH autoantibodies (P = 0.0052). Furthermore, the 21OH-specific production of interferon-gamma was enhanced in the presence of 21OH autoantibodies. This effect was partially inhibited by antibodies against the Fc receptor for IgG, CD32. Moreover, mature dendritic cells proved superior to the other antigen-presenting cells in invoking cellular responses to 21OH. An association between cellular immunity to 21OH and the high-risk HLA genotype for Addison's disease, DRB1*0301-DQ2/DRB1*0404-DQ8, was observed (P = 0.0089). Finally, a significant association between the DRB1*0404-DQ8 haplotype and cellular responses to a 21OH-derived peptide predicted to bind to DRB1*0404 was detected (P = 0.0055).
CONCLUSION: Patients with autoimmune Addison's disease have circulating 21OH-specific T cells, with amino acids 342-361 of 21OH possibly constituting a disease-specific epitope presented by HLA-DRB1*0404.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890026     DOI: 10.1210/jc.2009-1115

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Adrenal insufficiency.

Authors:  Stefanie Hahner; Richard J Ross; Wiebke Arlt; Irina Bancos; Stephanie Burger-Stritt; David J Torpy; Eystein S Husebye; Marcus Quinkler
Journal:  Nat Rev Dis Primers       Date:  2021-03-11       Impact factor: 52.329

Review 2.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

Review 3.  Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis.

Authors:  Eystein S Husebye; Mark S Anderson
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

Review 4.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

Review 5.  Insights into type 1 diabetes from the autoimmune polyendocrine syndromes.

Authors:  Mickie H Cheng; Mark S Anderson
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-08       Impact factor: 3.243

6.  The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease.

Authors:  A Hellesen; K Edvardsen; L Breivik; E S Husebye; E Bratland
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

7.  High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients.

Authors:  Amina Dawoodji; Ji-Li Chen; Dawn Shepherd; Frida Dalin; Andrea Tarlton; Mohammad Alimohammadi; Marissa Penna-Martinez; Gesine Meyer; Anna L Mitchell; Earn H Gan; Eirik Bratland; Sophie Bensing; Eystein S Husebye; Simon H Pearce; Klaus Badenhoop; Olle Kämpe; Vincenzo Cerundolo
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

8.  Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors.

Authors:  Anette S B Wolff; Jaanika Kärner; Jone F Owe; Bergithe E V Oftedal; Nils Erik Gilhus; Martina M Erichsen; Olle Kämpe; Anthony Meager; Pärt Peterson; Kai Kisand; Nick Willcox; Eystein S Husebye
Journal:  J Immunol       Date:  2014-09-17       Impact factor: 5.422

9.  APECED: is this a model for failure of T cell and B cell tolerance?

Authors:  Nicolas Kluger; Annamari Ranki; Kai Krohn
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

10.  The cytochrome P450 inhibitor, ketoconazole, inhibits oxidized linoleic acid metabolite-mediated peripheral inflammatory pain.

Authors:  Shivani Ruparel; Dustin Green; Paul Chen; Kenneth M Hargreaves
Journal:  Mol Pain       Date:  2012-09-24       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.